the aid library

Filter

8158

Pacote de formação sobre o Xpert MTB/RIF

USAID; WHO; FIND; et al. global laboratory initiative (2017) C_WHO

The modules (1-12) are based on materials originally developed by FIND, KNCV and Cepheid, and are in PowerPoint format for country customization. Depending on the audience, modules may be selected and adapted according to need (e.g. basic users, supervisors, clinicians). Topics covered include: Over ... more

Training Package on XPERT MTB/RIF

USAID; WHO; FIND; et al. global laboratory initiative (2017) C_WHO

The modules (1-12) are based on materials originally developed by FIND, KNCV and Cepheid, and are in PowerPoint format for country customization. Depending on the audience, modules may be selected and adapted according to need (e.g. basic users, supervisors, clinicians). Topics covered include: Over ... more

Healthy Living Toolkit

US Committee for Refugees and Immigrants (2015) CC

The Healthy Living Toolkit is developed to educate refugees, immigrants, resettlement agencies, clinics, community based organizations, and other service providers on refugee health issues. The toolkit presents material in a culturally appropriate manner and is intended to help health ... more

Global update on HIV treatment 2013: Results, impact and opportunities

World Health Organization; UNICEF; UNAIDS (2013)

Chapter 1 provides new data on the latest developments in the global treatment effort, highlighting positive trends as well as aspects that require improvement. Chapter 2 summarizes the impact of the scale-up in reducing AIDS-related mortality and new HIV infections. Chapter 3 examines the sequence ... more

National Implementation Guidelines for HIV and STI Programming Among Young Key Populations

NASCOP (National AIDS & STI Control Programme), Kenya (2018) CC

These guidelines were developed as part of Kenya's fast-track plan to end AIDS among adolescents and young people. Based on research into adolescent and young key populations in Kenya and elsewhere, they outline a package of HIV prevention services, and emphasize the need to combine biobehavioural i ... more

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended

World Health Organization (WHO) (2019) C_WHO

The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci ... more

UNHCR Global Strategy for Public Health 2021-2025

UN High Commissioner for Refugees UNHCR (2021) C1

UNHCR’s Public Health Strategy 2021-2025 is based on the lessons learnt, and builds on the achievements, of the Global Strategy for Public Health 2014-2018. Progress was made on policies favouring inclusion and integration into national systems3 with 92% of 48 operations surveyed reporting refuge ... more

Type 1 diabetes in adults

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2023) CC2

The document provides quality standards for managing Type 1 diabetes in adults, emphasizing areas like structured education, continuous glucose monitoring (CGM), cardiovascular risk management, and diabetic foot assessment. It aims to improve care p ... more

UNICEF’s HIV Programming in the Context of COVID-19: Building back better for children, adolescents and women

Unicef (2021) CC2

The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navigate an increased client load and demands at work while also being concerned for their own health and ... more

Type 2 diabetes in adults

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2023) CC2

The document provides the NICE Quality Standard for managing Type 2 diabetes in adults (QS209). It outlines evidence-based recommendations for preventing Type 2 diabetes, structured education, continuous glucose monitoring (CGM), medication such as SGLT2 inhibitors, and regular ... more

COVID-19: Chloroquine and hydroxychloroquine research

World Health Organization WHO (2020) C_WHO

This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing ... more

Сборник научных статей по материалам Конгресса ≪Психическое здоровье человека XXI века≫
recommended

Союз охраны психического здоровья, Issa, world council for psychotheraphy et al. Союз охраны психического здоровья, Issa, world council for psychotheraphy et al. (2016) C2

В сборнике представлены статьи специалистов в сфере охраны психического здоровья по различным академическим дисциплинам, включая общую медицину, психиатрию, пси� ... more

Estimated Burden of Fungal Infections in Namibia

Dunaiski, C. M.; Denning, D. W. (2019) CC2

J Fungi (Basel) . 2019 Aug 16;5(3):75. doi: 10.3390/jof5030075 . Namibia is a sub-Saharan country with one of the highest HIV infection rates in the world. Although care and support services are available that cater for opportunistic infections rela ... more

Combating false information on vaccines: A guide for health workers

Pan American Health Organization PAHO; World Health Organization WHO (2025) C_WHO

The document "Combating False Information on Vaccines: A Guide for Health Workers" is designed to help health workers address vaccine misinformation. It begins by defining misinformation and explaining why it spreads rapidly, often due to its emotional appeal and simplistic explanations. The guide i ... more

Combating false information on vaccines: A guide for EPI managers

Pan American Health Organization PAHO; World Health Organization WHO (2025) C_WHO

The document "Combating False Information on Vaccines: A Guide for EPI Managers" is designed to help Expanded Program on Immunization (EPI) managers address vaccine misinformation. It begins by defining misinformation and explaining why it spreads rapidly, often due to its emotional appeal and simpl ... more

MALARIA DIAGNOSTICS MARKET AND TECHNOLOGY LANDSCAPE 4th EDITION

World Health Organization WHO (2022) C_WHO

The 2022 report reviews the global malaria diagnostics market and technological landscape to support Unitaid’s 2023–2027 strategy for quality malaria case management. The report highlights the stalled progress of malaria control efforts, the gaps in access to diagnostics and the public health im ... more

National Strategic Plan for the Prevention and Control of Non-Communicable Diseases | 2021 - 2026

Word Health Organization WHO (2021) C_WHO

Non-Communicable Diseases (NCDs) have emerged as conditions of great public health concern in Kenya accounting for 39% of deaths annually. The Ministry of Health through the Department of Non-Communicable Diseases has adopted the vision of achieving a nation free from preventable burden of NCDs. Fur ... more

A journey towards Health in All Policies in Tanzania

World Health Organization WHO (2020) C_WHO

Health in All Policies (HiAP) promotes health and equity. It is based on the recognition that our greatest health challenges for example, non-communicable diseases, health inequities and inequalities, climate change, and spiraling health care costs ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Cardiovascular Diseases in Sub-Saharan Africa Compared to High-Income Countries: An Epidemiological Perspective

Yuyun, M.F.; Sliwa, K.; Kengne, A.P. et al. Global Heart (2020) CC

Non-communicable diseases (NCDs) are the second common cause of death in sub-Saharan Africa (SSA) accounting for about 35% of all deaths, after a composite of communicable, maternal, neonatal, and nutritional diseases. Despite prior perception of low NCDs mortality rates, current evidence suggests t ... more